Evidence map›Paper›PMID 30251128›Full record

SynthesisRheumatology international2018

Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence.

Santiago Muñoz-Fernández, Teresa Otón-Sánchez, Loreto Carmona, Jaime Calvo-Alén, Alejandro Escudero, Javier Narváez, Jose Manuel Rodríguez Heredia, Susana Romero Yuste, Paloma Vela, Sara Luján Valdés and 2 more

Abstract readConsensus StatementSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Rheumatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Musculoskeletal ultrasonography in rheumatic diseases.Turkish journal of medical sciences · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Santiago Muñoz-FernándezHospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain.ORCID 0000-0002-2758-2085
Teresa Otón-SánchezInstituto de Salud Musculoesquelética, InMusc, Calle Conde de la Cimera, 6, 28040, Madrid, Spain.ORCID 0000-0003-3622-7146
Loreto CarmonaInstituto de Salud Musculoesquelética, InMusc, Calle Conde de la Cimera, 6, 28040, Madrid, Spain. loreto.carmona@inmusc.eu.ORCID 0000-0002-4401-2551
Jaime Calvo-AlénHospital Universitario Araba, Vitoria, Spain.
Alejandro EscuderoComplejo Hospitalario Regional Reina Sofía, Córdoba, Spain.
Javier NarváezHospital Universitari de Bellvitge, Barcelona, Spain.ORCID 0000-0002-1614-8064
Jose Manuel Rodríguez HerediaHospital Universitario de Getafe, Madrid, Spain.
Susana Romero YusteComplexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
Paloma VelaHospital General Universitario de Alicante, Alicante, Spain.
Sara Luján ValdésMedical Department, Bristol-Myers Squibb, Madrid, Spain.
Ana Royo GarcíaMedical Department, Bristol-Myers Squibb, Madrid, Spain.
José Luis BaqueroScientiaSalus, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study is to benchmark the use and attributed importance of well-established prognostic factors in rheumatoid arthritis (RA) in daily clinical practice, and to contrast the use of factors with their ability to predict outcome. Medline was searched (inception-Sep. 2016) for systematic reviews on factors predicting death, disability, structural damage or remission in RA. All factors identified were compiled in a matrix of factors × outcomes, and scoping reviews for each cell were then performed. A survey to 42 rheumatologists randomly selected explored the use of the list of prognostic factors and inquired about the perceived strength of association with poor prognosis. In a second round, participants were exposed to evidence from the matrix and to responses from other participants. Change on perceived strength of association was evaluated. Rheumatologists report using prognostic factors in clinical practice on a daily basis. Very young onset, joint counts at diagnosis, rheumatoid factor, ACPA, and radiographic erosions are used frequently and correctly recognized as strong predictors. Comorbidities and other associated problems, such as obesity, low bone mineral density, cardiovascular disease, or extra-articular manifestations, are perceived as moderately associated to prognosis but, nevertheless, rheumatologists also use them profusely. Genetic and other biomarkers and osteitis by magnetic resonance are less accessible in daily practice and they obtained better results on second round (probably after knowing the strength of association with prognosis). Rheumatologists use widely most prognostic factors with a strong predictive value. However, factors with low evidence of prognostic value are also used and some factors are not used despite good evidence.

Indexed as

Decision Support TechniquesArthritis, RheumatoidAttitude of Health PersonnelBenchmarkingClinical Decision-MakingConsensusDelphi TechniqueEvidence-Based MedicineHealth Knowledge, Attitudes, PracticeHumansPredictive Value of TestsPrognosisRheumatologistsRheumatologyRisk AssessmentRisk FactorsClinical medicineEvidence-based practicePrognosisRheumatoid arthritisSystematic review

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.